Literature DB >> 19188823

Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.

Elizabeth G Munro1, Maneesh Jain, Esther Oliva, Neel Kamal, Subodh M Lele, Maureen P Lynch, Lankai Guo, Kai Fu, Poonam Sharma, Steve Remmenga, Whitfield B Growdon, John S Davis, Bo R Rueda, Surinder K Batra.   

Abstract

MUC4 is a transmembrane glycoprotein more highly expressed in cervical dysplasia than benign cervical epithelium. We sought to determine whether MUC4 expression differs between benign and malignant cervical tissue. Fifty-eight patients with benign, dysplastic, or malignant cervical pathology were identified retrospectively, and representative sections were stained with a mouse monoclonal anti-MUC4 antibody. Semiquantitative analysis was performed on benign, dysplastic, and malignant regions by scoring staining intensity (0: negative, 1: weak, 2: moderate, and 3: strong) and distribution (focal <10%, multifocal=10%-60%, diffuse > or =60%). In samples with benign glycogenated squamous epithelium, only the parabasal cells had MUC4 staining, and 48.5% had an intensity of 2 or 3. All samples with immature squamous metaplasia were positive through the entire epithelial thickness. Cervical intraepithelial neoplasia (CIN) 1 samples had variable staining with an intensity similar to glycogenated squamous epithelium but distribution similar to squamous metaplasia. All CIN 3 (n=21) and invasive squamous cell carcinomas (n=17) had increased MUC4 staining intensity (P<0.001 and P<0.001) and increased diffuse staining (P<0.001 and P<0.001) compared with the limited staining in glycogenated squamous epithelium. In contrast, no differences in staining were observed between benign endocervical glands, adenocarcinoma in situ, and invasive adenocarcinoma. These expression patterns suggest that MUC4 is a lineage marker in benign cervical tissue that may have aberrant expression in squamous dysplasia and carcinoma. Further studies may elucidate the role of MUC4 in the development of squamous cell cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188823      PMCID: PMC2932462          DOI: 10.1097/PGP.0b013e318184f3e0

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  27 in total

1.  Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways.

Authors:  Scott Jepson; Masanobu Komatsu; Bushra Haq; Maria E Arango; Daming Huang; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  Oncogene       Date:  2002-10-24       Impact factor: 9.867

Review 2.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

3.  Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance.

Authors:  M Andrianifahanana; N Moniaux; B M Schmied; J Ringel; H Friess; M A Hollingsworth; M W Büchler; J P Aubert; S K Batra
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

4.  MUC4 expression is increased in dysplastic cervical disorders.

Authors:  A López-Ferrer; F Alameda; C Barranco; M Garrido; C de Bolós
Journal:  Hum Pathol       Date:  2001-11       Impact factor: 3.466

Review 5.  Structural organization and classification of the human mucin genes.

Authors:  N Moniaux; F Escande; N Porchet; J P Aubert; S K Batra
Journal:  Front Biosci       Date:  2001-10-01

6.  Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study.

Authors:  G S Arul; M Moorghen; N Myerscough; D A Alderson; R D Spicer; A P Corfield
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix.

Authors:  Christophe Rosty; Jérôme Couturier; Anne Vincent-Salomon; Pascal Genin; Paul Fréneaux; Brigitte Sigal-Zafrani; Xavier Sastre-Garau
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

9.  Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy.

Authors:  Y Niibe; T Nakano; T Ohno; Y Suzuki; K Oka; H Tsujii
Journal:  Int J Gynecol Cancer       Date:  2003 Nov-Dec       Impact factor: 3.437

Review 10.  Cell signaling through membrane mucins.

Authors:  Kermit L Carraway; Victoria P Ramsauer; Bushra Haq; Coralie A Carothers Carraway
Journal:  Bioessays       Date:  2003-01       Impact factor: 4.345

View more
  11 in total

1.  Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Authors:  Albert C Chen; Ilenia Migliaccio; Mothaffar Rimawi; Sara Lopez-Tarruella; Chad J Creighton; Suleiman Massarweh; Catherine Huang; Yen-Chao Wang; Surinder K Batra; M Carolina Gutierrez; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2012-05-29       Impact factor: 4.872

Review 2.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

3.  Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.

Authors:  Subhankar Chakraborty; Benjamin J Swanson; Neelima Bonthu; Surinder K Batra
Journal:  J Clin Pathol       Date:  2010-07       Impact factor: 3.411

4.  Development of human ectocervical tissue models with physiologic endocrine and paracrine signaling†.

Authors:  Kelly E McKinnon; Rhitwika Sensharma; Chloe Williams; Jovanka Ravix; Spiro Getsios; Teresa K Woodruff
Journal:  Biol Reprod       Date:  2020-08-21       Impact factor: 4.285

5.  MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.

Authors:  Murielle Mimeault; Sonny L Johansson; Shantibhusan Senapati; Navneet Momi; Subhankar Chakraborty; Surinder K Batra
Journal:  Cancer Lett       Date:  2010-03-19       Impact factor: 8.679

6.  MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.

Authors:  I Lakshmanan; M P Ponnusamy; S Das; S Chakraborty; D Haridas; P Mukhopadhyay; S M Lele; S K Batra
Journal:  Oncogene       Date:  2011-07-25       Impact factor: 9.867

7.  Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer.

Authors:  Maneesh Jain; Ganesh Venkatraman; Nicolas Moniaux; Sukhwinder Kaur; Sushil Kumar; Subhankar Chakraborty; Grish C Varshney; Surinder K Batra
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

8.  Expression of Mucin 4 in leukoplakia and oral squamous cell carcinoma: An immunohistochemical study.

Authors:  Sangeetha Narashiman; Malathi Narasimhan; Ganesh Venkatraman
Journal:  J Oral Maxillofac Pathol       Date:  2014-01

9.  Identification of differentially-expressed genes by DNA methylation in cervical cancer.

Authors:  Heun-Sik Lee; Jun Ho Yun; Junghee Jung; Young Yang; Bong-Jo Kim; Sung-Jong Lee; Joo Hee Yoon; Yong Moon; Jeong-Min Kim; Yong-Il Kwon
Journal:  Oncol Lett       Date:  2015-01-29       Impact factor: 2.967

Review 10.  Cell membrane-anchored MUC4 promotes tumorigenicity in epithelial carcinomas.

Authors:  Pengpeng Xia; Agnes Hakyung Choi; Zengping Deng; Yuqian Yang; Jing Zhao; Yiting Wang; Philip R Hardwidge; Guoqiang Zhu
Journal:  Oncotarget       Date:  2017-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.